Immune Phenotypes That Are Associated with Subsequent COVID-19 Severity Inferred from Post-recovery Samples
Overview
Authors
Affiliations
Severe COVID-19 causes profound immune perturbations, but pre-infection immune signatures contributing to severe COVID-19 remain unknown. Genome-wide association studies (GWAS) identified strong associations between severe disease and several chemokine receptors and molecules from the type I interferon pathway. Here, we define immune signatures associated with severe COVID-19 using high-dimensional flow cytometry. We measure the cells of the peripheral immune system from individuals who recovered from mild, moderate, severe or critical COVID-19 and focused only on those immune signatures returning to steady-state. Individuals that suffered from severe COVID-19 show reduced frequencies of T cell, mucosal-associated invariant T cell (MAIT) and dendritic cell (DC) subsets and altered chemokine receptor expression on several subsets, such as reduced levels of CCR1 and CCR2 on monocyte subsets. Furthermore, we find reduced frequencies of type I interferon-producing plasmacytoid DCs and altered IFNAR2 expression on several myeloid cells in individuals recovered from severe COVID-19. Thus, these data identify potential immune mechanisms contributing to severe COVID-19.
Neutrophils restricted contribution of genetic variants to COVID-19 severity.
Laffranchi M, Paraboschi E, Bianchetto-Aguilera F, Tamassia N, Gasperini S, Gardiman E Heliyon. 2025; 11(1):e41267.
PMID: 39811276 PMC: 11731188. DOI: 10.1016/j.heliyon.2024.e41267.
The role of inflammatory gene polymorphisms in severe COVID-19: a review.
Yip J, Oo A, Ng Y, Chin K, Tan K, Chu J Virol J. 2024; 21(1):327.
PMID: 39707400 PMC: 11662554. DOI: 10.1186/s12985-024-02597-3.
T Regulatory Cell Subsets Do Not Restore for One Year After Acute COVID-19.
Aquino A, Zaikova E, Kalinina O, Karonova T, Rubinstein A, Mikhaylova A Int J Mol Sci. 2024; 25(21).
PMID: 39519310 PMC: 11545974. DOI: 10.3390/ijms252111759.
Impaired mucosal IgA response in patients with severe COVID-19.
Yaugel-Novoa M, Noailly B, Jospin F, Pizzorno A, Traversier A, Pozzetto B Emerg Microbes Infect. 2024; 13(1):2401940.
PMID: 39358866 PMC: 11451292. DOI: 10.1080/22221751.2024.2401940.
Restricting datasets to classifiable samples augments discovery of immune disease biomarkers.
Glehr G, Riquelme P, Kronenberg K, Lohmayer R, Lopez-Madrona V, Kapinsky M Nat Commun. 2024; 15(1):5417.
PMID: 38926389 PMC: 11208602. DOI: 10.1038/s41467-024-49094-3.